Zobrazeno 1 - 10
of 101
pro vyhledávání: '"László B, Tankó"'
Autor:
David Demanse, Franziska Saxer, Patrick Lustenberger, László B. Tankó, Philipp Nikolaus, Ilja Rasin, Damian F. Brennan, Ronenn Roubenoff, Sumehra Premji, Philip G Conaghan, Matthias Schieker
Publikováno v:
Seminars in Arthritis and Rheumatism. 58:152140
Osteoarthritis (OA) is a complex disease comprising diverse underlying patho-mechanisms. To enable the development of effective therapies, segmentation of the heterogenous patient population is critical. This study aimed at identifying such patient c
Autor:
Thomas I. Cochrane, Kumaraswamy Sivakumar, Hardik Ashar, László B. Tankó, Anthony A. Amato, Birgitte Sloth, Didier Laurent
Publikováno v:
Neurology. 95(14)
ObjectiveTo assess the long-term safety and tolerability and to monitor benefits of extended use of bimagrumab in individuals with sporadic inclusion body myositis (sIBM) who completed a single-dose core study.MethodsIn this multicenter, open-label e
Autor:
László B. Tankó, Jan-Erik Damber, Sirpa Aaltomaa, Peter Klarskov, Haluk Ozen, Karol Axcrona, Carlos Silva, Enrico Colli
Publikováno v:
BJU International. 110:1721-1728
Study Type – Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Androgen deprivation therapy (ADT) is commonly used as a primary treatment for patients with prostate cancer (PCa) who are not eligible for ra
Publikováno v:
Journal of Urology. 186:1835-1842
We investigated associations of baseline cardiovascular disease risk profile, dosing regimen and treatment duration with incident cardiovascular disease events during androgen deprivation therapy with degarelix in patients with prostate cancer.Data o
Autor:
László B. Tankó, Birgitte Buur Rasmussen, Wolfgang Koechling, Jacek Stalewski, Anders Sonesson
Publikováno v:
Drug Metabolism and Disposition. 39:1895-1903
Degarelix is a novel competitive gonadotropin-releasing hormone receptor blocker (antagonist). In this study, the nonclinical metabolism and excretion of degarelix was investigated in Sprague-Dawley rat, beagle dog, and cynomolgus monkey. Degarelix w
Publikováno v:
British Journal of Clinical Pharmacology. 70:580-587
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT? • Systemic anaphylactic reactions have been described as rare but serious adverse effects of GnRH antagonists. • The chemical development of degarelix has devoted much attention to the elimination of this
Publikováno v:
IEEE Transactions on Medical Imaging. 27:1054-1060
We investigate the possibility to develop methodologies for assessing effect specific structural changes of the breast tissue using a general statistical machine learning framework. We present an approach of obtaining objective mammographic pattern m
Publikováno v:
Journal of Endocrinology. 199:61-68
The presence of peripheral fat mass (PFM) appears to counteract the atherogenic trends of central fat mass through mechanisms presently poorly understood. In elderly women with distinct forms of body fat distribution, we wanted to study whether physi
Publikováno v:
Climacteric. 11:4-16
To review cellular mechanisms that have been proposed to mediate the indirect and direct effects of estrogen on articular cartilage, and to outline the remaining clinical questions that need to be clarified before utilizing the beneficial effects of
Autor:
Mads Nielsen, Marco Loog, P.C. Pettersen, Claus Christiansen, Jakob Raundahl, László B. Tankó
Publikováno v:
Climacteric. 11:135-143
First, to compare the impact of nasally and orally dosed estradiol on breast density; second, to investigate the utility of computer-based automated approaches to the assessment of breast density with reference to traditional methods.Digitized images